Antitrombotik ve Antikoagülan Kullanım İlkeleri

Heparin, heparin-derived compounds and warfarinhave been successfully used for the prevention andtreatment of venous thromboembolism during last 50years. Low-molecular-weight heparins are alternativedrugs to unfractionated heparin because of pharma-cokinetic and pharmacodynamic features nowadays.Warfarin is still a gold standard anticoagulant oralagent. However, there are some limitations of thesementioned drugs. It is needed the new oral and par-enteral anticoagulant drugs to solve these limitations.There are several preclinical and clinical studies onefficacy and safety of new drugs such as paren-teral FXa inhibitors (idraparinux and idraparinux-biotincomplex) and oral FXa inhibitor (rivaroxaban-Xiralto)and oral FIIa inhibitor (dabigatran-Pradaxa). Both riva-roxaban and dabigatran are newly approved for shortterm usage on the prevention of VTE during orthope-dic procedures such as hip and knee replacement.